From StockTwits: 2025-04-15 04:52:00

Pfizer Inc. has decided to halt the development of its oral GLP-1 candidate due to potential liver toxicity, which could benefit smaller biotech rivals like Structure Therapeutics and Viking Therapeutics. JPMorgan believes Structure’s aleniglipron could be the second small molecule oral GLP-1 on the market, while BTIG sees Viking as an attractive partnership candidate with a 400% upside potential. Retail sentiment for Viking turned bullish, with speculation that Pfizer may consider acquiring the company. Structure Therapeutics also saw a surge in sentiment, with users praising its aleniglipron as a top contender in the GLP-1 market.



Read more at StockTwits: Wall Street Sees Pfizer’s Weight-Loss Pill Exit As A Win For Viking, Structure Therapeutics